Dr. Wagner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
535 Barnhill Dr
Indianapolis, IN 46202Phone+1 317-944-8660Fax+1 317-278-1302
Education & Training
- University of Louisville School of MedicineFellowship, Hematology and Medical Oncology, 2004 - 2007
- Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 2001 - 2004
- Ross University School of MedicineClass of 2001
Certifications & Licensure
- OH State Medical License Current
- IN State Medical License 2008 - 2025
- KY State Medical License 2004 - 2015
- NC State Medical License 2007 - 2009
- MI State Medical License 2001 - 2004
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
- Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
- Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
Publications & Presentations
PubMed
- 175 citationsAssociation of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A P...Linda M Liau, Keyoumars Ashkan, Steven Brem, Jian L Campian, John E Trusheim
JAMA Oncology. 2023-01-01 - 23 citationsDetection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer.Sakti Chakrabarti, Leslie Bucheit, Jason Scott Starr, Racquel Innis-Shelton, Ardaman Shergill
Journal for Immunotherapy of Cancer. 2022-06-01 - 24 citationsA randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinomaSara Kochanny, Francis P. Worden, Douglas Adkins, D. Lim, Julie E. Bauman
Cancer. 2020-05-15
Press Mentions
- Oncologist Brings Specialty to Columbus RegionalOctober 2nd, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: